This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Rubitecan
- DrugBank Accession Number
- DB06159
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 393.355
Monoisotopic: 393.096085215 - Chemical Formula
- C20H15N3O6
- Synonyms
- 9-NC
- 9-nitro-(20S)-camptothecin
- 9-nitro-20(S)-camptothecin
- 9-nitrocamptothecin
- 9NC
- Rubitecan
- Rubitecán
- Rubitécan
- Rubitecanum
- External IDs
- RF-2000
- RFS 2000
- RFS-2000
- RFS2000
Pharmacology
- Indication
Investigated for use/treatment in pancreatic cancer, leukemia (unspecified), melanoma, ovarian cancer, and cancer/tumors (unspecified).
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
- Pharmacodynamics
Not Available
- Mechanism of action
Rubitecan prevents DNA from unwinding during replication via DNA topoisomerase 1, therefore interfering with tumor growth.
Target Actions Organism UDNA topoisomerase 1 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareDarbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rubitecan. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Rubitecan. Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rubitecan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Rubitecan. Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Camptogen / Orathecin (Supergen)
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- H19C446XXB
- CAS number
- 91421-42-0
- InChI Key
- VHXNKPBCCMUMSW-FQEVSTJZSA-N
- InChI
- InChI=1S/C20H15N3O6/c1-2-20(26)13-7-16-17-10(8-22(16)18(24)12(13)9-29-19(20)25)6-11-14(21-17)4-3-5-15(11)23(27)28/h3-7,26H,2,8-9H2,1H3/t20-/m0/s1
- IUPAC Name
- (19S)-19-ethyl-19-hydroxy-8-nitro-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione
- SMILES
- CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC=C(C1=C3)[N+]([O-])=O)C2=O
References
- General References
- Not Available
- External Links
- KEGG Drug
- D04031
- PubChem Compound
- 11954380
- ChemSpider
- 414807
- ChEBI
- 90225
- ChEMBL
- CHEMBL77305
- ZINC
- ZINC000003827362
- Wikipedia
- Rubitecan
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Unknown Status Treatment Malignant Neoplasm of Pancreas 3 2 Completed Treatment Bladder Cancer, Cancer / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer 1 2 Completed Treatment Brain and Central Nervous System Tumors 1 2 Completed Treatment Breast Cancer 1 2 Completed Treatment Cancer / Lung Disorder 1 2 Completed Treatment Corpus Uteri / Endometrial Cancer 1 2 Completed Treatment Gastrointestinal Stromal Tumor (GIST) / Sarcomas / Small Intestine Cancer 1 2 Completed Treatment Lung Cancers 2 2 Completed Treatment Melanoma 1 2 Completed Treatment Ovarian Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.239 mg/mL ALOGPS logP 1.88 ALOGPS logP 1.16 ChemAxon logS -3.2 ALOGPS pKa (Strongest Acidic) 11.71 ChemAxon pKa (Strongest Basic) 0.29 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 122.87 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 100.81 m3·mol-1 ChemAxon Polarizability 38.87 Å3 ChemAxon Number of Rings 5 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.7977 Blood Brain Barrier - 0.6125 Caco-2 permeable - 0.8307 P-glycoprotein substrate Substrate 0.5853 P-glycoprotein inhibitor I Non-inhibitor 0.7775 P-glycoprotein inhibitor II Non-inhibitor 0.9611 Renal organic cation transporter Non-inhibitor 0.8838 CYP450 2C9 substrate Non-substrate 0.8475 CYP450 2D6 substrate Non-substrate 0.8388 CYP450 3A4 substrate Substrate 0.6054 CYP450 1A2 substrate Inhibitor 0.6135 CYP450 2C9 inhibitor Non-inhibitor 0.647 CYP450 2D6 inhibitor Non-inhibitor 0.8503 CYP450 2C19 inhibitor Non-inhibitor 0.6043 CYP450 3A4 inhibitor Inhibitor 0.6262 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.6372 Ames test AMES toxic 0.7389 Carcinogenicity Non-carcinogens 0.6422 Biodegradation Not ready biodegradable 0.9971 Rat acute toxicity 2.7520 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9616 hERG inhibition (predictor II) Non-inhibitor 0.862
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsDNA topoisomerase 1
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Poly(a) rna binding
- Specific Function
- Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a singl...
- Gene Name
- TOP1
- Uniprot ID
- P11387
- Uniprot Name
- DNA topoisomerase 1
- Molecular Weight
- 90725.19 Da
References
- Chedid S, Rivera E, Frye DK, Ibrahim N, Esteva F, Valero V, Hortobagyi G, Mettinger KL, Cristofanilli M: Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2006 Apr;57(4):540-4. Epub 2005 Sep 29. [Article]
Drug created at March 19, 2008 16:14 / Updated at February 21, 2021 18:52